Kazia Therapeutics (ASX:KZA) - CEO, James Garner
CEO, James Garner
Source: Kazia Therapeutics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Kazia Therapeutics (KZA) is granted patents for the manufacture of Paxalisib by agencies in the US and India
  • The original patents for Paxalisib protect its chemical structure, while the new manufacturing patents cover the process by which Paxalisib is made
  • The new patents will expire in 2036, but are likely to be eligible for a five-year patent term extension
  • Kazia Therapeutics is up 2.31 per cent, trading at $1.33 per share at 1:36 pm AEST

Kazia Therapeutics (KZA) has been granted patents for the manufacture of Paxalisib by agencies in the US and India.  

Paxalisib is a brain-penetrant inhibitor which is being developed to treat glioblastoma, the most common and agressive form of primary brain cancer in adults.

The original patents for Paxalisib protect its chemical structure. The newly granted manufacturing patents provide an additional layer of protection for the company by covering the process by which Paxalisib is made. This means competitors would need to develop an alternative method of chemical synthesis to create the treatment, which is said to be challenging and costly.

The new patents will expire in 2036, but are likely to be eligible for a five-year patent term extension.

A similar patent has already been accepted in Australia and is expected to proceed to grant in the third quarter of 2021.

Kazia CEO James Garner said: “As we move towards commercialisation, we have worked closely with our IP counsel to ensure we achieve the maximum possible degree and duration of protection for the intellectual property embodied in Paxalisib.”

Further patents still remain pending in Europe, China, Canada and other territories, which the company expects to be approved in due course.

Kazia Therapeutics was up 2.31 per cent, trading at $1.33 per share at 1:36 pm AEST.

KZA by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…